Literature DB >> 24076396

Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability.

Boontida Morakul1, Jiraphong Suksiriworapong, Jiraporn Leanpolchareanchai, Varaporn Buraphacheep Junyaprasert.   

Abstract

Nanocrystals is one of effective technologies used to improve solubility and dissolution behavior of poorly soluble drugs. Clarithromycin is classified in BCS class II having low bioavailability due to very low dissolution behavior. The main purpose of this study was to investigate an efficiency of clarithromycin nanocrystals preparation by precipitation-lyophilization-homogenization (PLH) combination method in comparison with high pressure homogenization (HPH) method. The factors influencing particle size reduction and physical stability were assessed. The results showed that the PLH technique provided an effective and rapid reduction of particle size of nanocrystals to 460 ± 10 nm with homogeneity size distribution after only the fifth cycle of homogenization, whereas the same size was attained after 30 cycles by the HPH method. The smallest nanocrystals were achieved by using the combination of poloxamer 407 (2%, w/v) and SLS (0.1%, w/v) as stabilizers. This combination could prevent the particle aggregation over 3-month storage at 4 °C. The results from SEM showed that the clarithromycin nanocrystals were in cubic-shaped similar to its initial particle morphology. The DSC thermogram and X-ray diffraction pattern of nanocrystals were not different from the original drug except for intensity of peaks which indicated the presenting of nanocrystals in the crystalline state and/or partial amorphous form. In addition, the dissolution of the clarithromycin nanocrystals was dramatically increased as compared to the coarse clarithromycin.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clarithromycin; HPH; High pressure homogenization; Nanocrystals; PLH; Poorly soluble drug; Precipitation-lyophilization-homogenization; high pressure homogenization; precipitation-lyophilization-homogenization

Mesh:

Substances:

Year:  2013        PMID: 24076396     DOI: 10.1016/j.ijpharm.2013.09.022

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study.

Authors:  Naresh Mittapelly; Maharshi Thalla; Gitu Pandey; Venkatesh Teja Banala; Shweta Sharma; Abhishek Arya; Sandeep Mishra; Kalyan Mitra; Shubha Shukla; Prabhat Ranjan Mishra
Journal:  Pharm Res       Date:  2017-08-14       Impact factor: 4.200

2.  In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions-a metabolic approach.

Authors:  Luciana Damacena Silva; Nayana Ferreira Lima; Eva Carolina Arrua; Claudio Javier Salomon; Marina Clare Vinaud
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity.

Authors:  Salma M Mohyeldin; Mohammed M Mehanna; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2016-05-19

4.  Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability.

Authors:  Hany S M Ali; Ahmed F Hanafy; Abdulmalik Alqurshi
Journal:  Int J Nanomedicine       Date:  2019-03-13

Review 5.  Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery.

Authors:  Tao Liu; Xinxin Yu; Haipeng Yin; Jan P Möschwitzer
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

Review 6.  The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs.

Authors:  Dmitry Chistyakov; Gleb Sergeev
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.